Match!
Aaron S. Kesselheim
Harvard University
SurgeryIntensive care medicineMedical prescriptionFamily medicineMedicine
496Publications
44H-index
7,313Citations
What is this?
Publications 498
Newest
#1Benjamin N. Rome (Harvard University)H-Index: 10
#2Frazer A. Tessema (Brigham and Women's Hospital)H-Index: 3
Last. Aaron S. Kesselheim (Harvard University)H-Index: 44
view all 3 authors...
Importance Market exclusivity for daily injections of glatiramer acetate, a disease-modifying therapy for multiple sclerosis, expired in 2015. In 2014, the manufacturer launched an alternate 3-times-weekly version that was widely adopted, sustaining market dominance of brand-name glatiramer until late 2017. Objective To estimate excess US spending associated with the transition from daily to 3-times-weekly glatiramer. Design, Setting, and Participants This economic evaluation estimated total US ...
1 CitationsSource
#1Benjamin N. Rome (Harvard University)H-Index: 10
#2ChangWon C. Lee (Brigham and Women's Hospital)H-Index: 1
Last. Aaron S. Kesselheim (Harvard University)H-Index: 44
view all 3 authors...
Brand-name drugs have periods of market exclusivity before generic competition begins. Due to high brand-name drug prices charged during this period, market exclusivity is an important determinant of US prescription drug spending. We used claims data to estimate the market exclusivity period for 264 small molecule and 4 biologic drugs that faced new generic or biosimilar competition from 2012-2018. Exclusivity periods were longer for biologics compared to new small molecule drugs (median 21.5 vs...
Source
#1Victoria D. Lauenroth (Harvard University)
#2Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
Last. Ariel Dora Stern (Harvard University)H-Index: 10
view all 4 authors...
Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly pronounced in the US, it remains largely unaddressed there. In Euro...
Source
#1Reed F. Beall (U of C: University of Calgary)H-Index: 7
#2Paul E. Ronksley (U of C: University of Calgary)H-Index: 20
Last. Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
view all 6 authors...
Our objective was to compare expected and observed biosimilar and generic entry dates for a recent cohort of brand-name drugs. Therefore, we estimated expected biosimilar and generic entry dates for all 328 new drugs approved by the Food and Drug Administration (FDA) between 2000-2012, which we defined as the later of the expiration of the key patent term or statutory exclusivity (12 years for biologics, 5 years for small-molecule drugs not indicated for a rare disease, and 7 years for small-mol...
Source
#1Ameet Sarpatwari (Brigham and Women's Hospital)H-Index: 13
#2Anna Kaltenboeck (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
view all 3 authors...
Source
#1Jonathan J. Darrow (Brigham and Women's Hospital)H-Index: 11
#2Jessica E Chong (Brigham and Women's Hospital)
Last. Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
view all 3 authors...
Despite high rates of generic prescribing, branded medicines still account for most drug costs. Amending the law to provide pharmacists with greater authority to substitute clinically similar alternatives has the potential to cut spending, say Jonathan Darrow and colleagues
Source
False Negative Tests for SARS-CoV-2 Infection Diagnostic testing for SARS-CoV-2 will help in safely reopening the country, but only if tests are highly accurate. Several steps need to be taken by m...
13 CitationsSource
Specialty Drugs — A Distinctly American Phenomenon Various stakeholders in the pharmaceutical supply chain assign the specialty label to drugs on the basis of a combination of several unrelated fac...
Source
#1Jonathan J. Darrow (Brigham and Women's Hospital)H-Index: 11
#2Mehdi Najafzadeh (Brigham and Women's Hospital)H-Index: 18
Last. Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
view all 4 authors...
Summary Antimicrobial resistance is of growing concern. To encourage development of new treatments, some commentators have suggested regulators exercise increased flexibility on the clinical evidence required for approval. We examined all 1065 new drugs and biologics approved by the US Food and Drug Administration between 1984 and 2018 and recorded each drug's use of the Orphan Drug Act, fast-track, priority review, accelerated approval, and breakthrough therapy programmes, as well as dates of i...
Source
#1Chintan V. Dave (Brigham and Women's Hospital)H-Index: 7
#2Michael S. Sinha (Brigham and Women's Hospital)H-Index: 7
Last. Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
view all 4 authors...
Delays in market entry of generic drugs are common. This study sought to identify the prevalence of delayed entry, the reasons for the delays, and the delays’ effects on Medicaid spending in a rece...
Source
12345678910